Briacell Therap (NASDAQ:BCTX) Stock Price Up 1.8% – Here’s Why

Briacell Therap (NASDAQ:BCTX) shares traded up 1.8% during trading on Tuesday . The stock traded as high as $3.58 and last traded at $3.45. Approximately 61,830 shares changed hands during trading, a decline of 41% from the average daily volume of 105,626 shares. The stock had previously closed at $3.39.

Analyst Upgrades and Downgrades

BCTX has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday, July 17th. Wall Street Zen upgraded Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Briacell Therap has a consensus rating of “Sell”.

Briacell Therap Stock Up 1.8%

The firm has a market capitalization of $30.02 million, a P/E ratio of -0.44 and a beta of 1.14. The business’s 50 day moving average is $3.34 and its 200-day moving average is $3.81.

Briacell Therap (NASDAQ:BCTX) last released its earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share for the quarter.

Institutional Trading of Briacell Therap

An institutional investor recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.